Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
10,710 total articles
David M. McCoy, a director at Ridgepost Capital, Inc. (RPC), reported a sale of 70,000 Class A Common shares on March 23, 2026, for $515,900, according to a Form 4 filing. The company, formerly P10, is trading near its 52-week low as it rolls out a new ticker and expands operations in the Middle East while forming distribution partnerships for alte…
Tempest Therapeutics NASDAQ:TPST disclosed that CEO and president Angel Matthew purchased 231,482 shares of common stock on March 24, 2026, paying $2.16 per share for a total of $500,001. The transaction was executed indirectly through Factor Bioscience Inc., where Mr. Matthew serves as CEO and chairman. The purchase occurs against a backdrop of a …
Jonathan B. Fairbanks, a director and 10% owner of Flowco Holdings Inc (EXCHANGE:FLOC), indirectly sold 7,904,090 shares of Class A common stock on March 23, 2026, at $21.175 per share for a total of $165,165,000. On the same date he reported an indirect acquisition of 7,621,511 Class A shares through conversion of LLC interests at a zero price. Se…
Director John D. Baker II bought 478,468 shares of FRP Holdings, Inc. (NASDAQ: FRPH) on March 23, 2026, for $20.9 per share, a transaction valued at $9,999,981. The purchase raises Baker's total direct and indirect holdings to 3,050,243 shares amid a share price that has fallen about 27% over the past year and sits close to its 52-week low of $20.5…
EverCommerce Inc. CEO Eric Richard Remer sold 19,200 shares of the company on March 24 and 25, 2026, for a total of $207,974 under a Rule 10b5-1 plan. The transactions left Remer with 2,514,517 directly held shares and several larger indirect holdings. The trades follow EverCommerce's fourth-quarter 2025 report, which included a revenue beat but an…
BKV Corp Chief Executive Officer Christopher P. Kalnin sold 100,000 shares of the company’s common stock on March 25, 2026, generating $3,005,790 at weighted average prices between $30.00 and $30.14. The transaction was carried out under a previously arranged Rule 10b5-1 plan adopted on December 8, 2025. The sale takes place while BKV shares have c…
Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick completed insider stock sales totaling $9,048,290 across two trades on March 23 and March 25, disposing of 95,077 shares at prices between $76.7329 and $80.2586. On those same dates, Chadwick exercised options to buy 109,127 shares at $29.64 per share. The transactions were carried out …
Hyperfine Chief Operating Officer Thomas Teisseyre sold 24,188 Class A shares on March 23, 2026, for $1.21 per share, totaling $29,267, according to a Form 4 filed with the SEC. The sale, executed to meet tax withholding obligations from vested restricted stock units granted March 31, 2025, leaves Teisseyre with 354,648 shares. The transaction coin…
10x Genomics Chief Executive Officer Serge Saxonov sold 15,000 shares of Class A Common Stock on March 23 and 24, 2026, in transactions totaling $288,908, according to a Form 4 filing. The sales were executed under a Rule 10b5-1 plan adopted November 29, 2025. The trades occurred while TXG shares have risen more than 103% over the last year and wer…
22NW Fund, LP, a reported ten-percent holder of L.B. Foster Company (NASDAQ: FSTR), sold 106,919 shares of common stock over three trading days in late March 2026, generating about $3.04 million. The Form 4 filing shows the sales occurred March 23-25 and that the related filing was submitted jointly by a group of affiliated entities. The company’s …
Prosperity Bancshares director Holmes Ned S reported the sale of 1,100 shares of common stock on March 25, 2026, in three trades totaling $72,867. The transactions were executed at prices between $66.1788 and $66.2513. Following the sales, Holmes retains substantial direct and indirect holdings. Separately, Prosperity Bancshares reported fourth-qua…
Terrance P. Coyne, Executive Vice President and CFO of Royalty Pharma plc (NASDAQ: RPRX), sold 34,791 Class A ordinary shares under a pre-arranged 10b5-1 trading plan on March 23, 2026, generating roughly $1.58 million in proceeds. The transactions, executed at a weighted average price of $45.5287 within a $45.30 to $45.94 range, included indirect …
Jabil Inc. senior vice president and chief human resources officer Gary K. Schick sold 1,000 shares on March 24, 2026, for $278,332. The transaction leaves Schick with 40,843 Jabil shares. The company reported strong fiscal second-quarter results, raised full-year guidance and drew positive analyst reactions, while also committing $1.1 million to a…
Jabil Inc. director Anousheh Ansari sold 1,000 shares on March 24, 2026, generating $270,000 in proceeds. The stock has continued higher since the sale, trading above $283 and near its 52-week high. The transaction comes as Jabil reported strong second-quarter fiscal 2026 results, raised full-year guidance and received multiple analyst price-target…
Allison C. Hoffman, Phreesia's general counsel and secretary, sold 6,176 shares of the company's common stock on March 23, 2026, under a Rule 10b5-1 plan adopted in December 2025. The transaction totaled $73,926 and left Hoffman with 163,485 shares. Separately, Phreesia refinanced its bridge loan with a new $275 million senior secured revolving cre…
Okta Chief Executive Officer Todd McKinnon sold 11,263 shares of Class A common stock on March 23, 2026, receiving about $912,363 in proceeds. The trades were executed under a Rule 10b5-1 plan adopted in April 2025. The company is moving ahead with an AI agent security product scheduled for general availability on April 30, 2026, and has attracted …
David A. Duffield, a roughly 10% owner of Workday Inc (NASDAQ: WDAY), sold 107,500 shares of Class A Common Stock on March 23, 2026, in multiple tranches for about $14.7 million under a pre-arranged Rule 10b5-1 plan. The same day he converted 107,500 Class B shares into Class A shares; after the transactions he directly holds 105,049 Class A shares…
Verisign director Courtney D. Armstrong bought 15.909 shares on November 25, 2025, through The Armstrong Family Trust at $250.17 per share for a total of $3,979. The transaction raises the trust's holding to 5,203.471 shares while Armstrong also holds 882.244 shares directly. The domain registry operator, with a market value of $23.07 billion, was …
Director Christopher Gibson sold 40,000 shares of Recursion Pharmaceuticals Class A common stock at $3.25 per share on March 23, 2026, generating $130,000 in proceeds as the stock trades close to its 52-week low. On the same day he converted 40,000 Class B shares into Class A shares at no cost. After these moves, Gibson directly holds 906,556 Class…
Maureen Lally-Green, a director at CNX Resources Corp, sold 23,631 shares on March 23, 2026, for about $933,815 at prices between $39.5143 and $40. She also exercised options to buy 29,915 shares at $13.187 each for $394,489. The company has active debt restructuring moves, including a $500 million private placement of senior notes due 2034 and a t…
Yelp Inc. Chief Financial Officer David A. Schwarzbach sold 7,500 shares on March 23, 2026 at $25.00 per share, a transaction totaling $187,500. The sale, performed under a 10b5-1 trading plan adopted in August 2025, leaves Schwarzbach with 216,800 shares. Yelp reported a stronger-than-expected fourth quarter of 2025, but its guidance for 2026 unde…
Slide Insurance Holdings Chief Risk Officer Matthew Paul Larson sold 11,250 shares on March 24, 2026, realizing $202,500, after exercising options to acquire the same number of shares at $0.79 each. The stock trades below InvestingPro's stated fair value even as the company reported robust fourth-quarter 2025 results, completed a $120 million repur…
LivePerson Inc. CEO Anthony John Sabino sold 8,033 shares on March 23, 2026, for roughly $20,082 under a Rule 10b5-1 trading plan adopted in November 2025. The stock has fallen sharply over the past year and the company reported mixed fourth-quarter 2025 results, with a sizable earnings miss offset by a revenue beat.
Rachel Humphrey, a director at Pyxis Oncology, executed three sales of company stock in April 2025 under a Rule 10b5-1 trading plan, disposing of a total $15,917 worth of shares. The transactions were disclosed on a Form 4 with the SEC and follow notable clinical trial enrollment milestones and several analyst updates on the company.
Joseph Gebbia, an Airbnb director and roughly 10% owner, sold 60,000 shares of Class A common stock on March 23, 2026, for $7,685,662 in aggregate, according to a Form 4 filing. The trades were executed in several tranches at prices between $130.4267 and $133.2693. After the sales, Gebbia, through Sycamore Trust, indirectly holds 244,018 shares and…
